title: The role of concurrent chemotherapy to intensity-modulated radiotherapy (IMRT) after neoadjuvant docetaxel and cisplatin treatment in locoregionally advanced nasopharyngeal carcinoma.
abstract: The goal of this study was to assess the efficacy of concurrent chemotherapy to intensity-modulated radiotherapy (IMRT) after neoadjuvant chemotherapy (NACT) in locoregionally advanced nasopharyngeal carcinoma (NPC). A total of 120 patients with stage III-IVB NPC treated with NACT followed by IMRT alone (39 patients, arm 1) or CCRT (81 patients, arm 2) between May 2009 and June 2012 were eligible for study inclusion. NACT consisted of docetaxe (DOC, 60 mg/m(2), day 1) and cisplatin (DDP, 100 mg/m(2), days 1-5, every 3 weeks). Concurrent chemotherapy was nedaplatin (NDP, 25 mg/m(2), days 1-3, every 3 weeks). The median follow-up period was 41 (range 5-52) months, and the 3-year overall survival, distant metastases-free survival, locoregional relapse-free survival, and progression-free survival rates of arm 1 and arm 2 were 83.3 and 87.4% (P = 0.516), 81.7 and 79.6% (P = 0.596), 86 and 92.3% (P = 0.920), 76.4 and 76.4% (P = 0.709), respectively. During radiotherapy, the most commonly recorded grade 3/4 adverse events were anemia (7.7 vs. 4.9%), leucopenia (10.2 vs. 3.7%), thrombocytopenia (12.8 vs. 3.7%), neutropenia (15.4 vs. 6.2%), nausea/vomiting (7.7 vs. 12.3%), stomatitis/mucositis (38.5 vs. 46.9%), xerostomia (35.9 vs. 30.8%), dermatitis (7.7 vs. 7.4%), and fatigue(15.4 vs. 17.2%) for arm 1 and arm 2. The results of this study indicated that added concurrent chemotherapy to IMRT after neoadjuvant DOC and DDP treatment for locoregionally advanced NPC was probably not be necessary.
authors: School of Nuclear Science and Technology, University of South China, 28 Changsheng West Road, Hengyang, 421001, Hunan, People's Republic of China.
authors: Lei
authors: L
authors: Zhang
authors: Guo-ping
authors: GP
authors: Shan
authors: Pu
authors: P
authors: Li
authors: Ping-jing
authors: PJ
authors: Cheng
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma; D059248:Chemoradiotherapy / Q000009:adverse effects* / Q000379:methods; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D020360:Neoadjuvant Therapy; D011379:Prognosis; D050397:Radiotherapy, Intensity-Modulated; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin
references: Science. 2008 Aug 29;321(5893):1154-5
references: 18755954
references: Head Neck. 2014 Oct;36(10):1474-80
references: 23996842
references: Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1440-50
references: 15590175
references: Oral Oncol. 2011 Jul;47(7):660-4
references: 21596616
references: J Clin Oncol. 2002 Apr 15;20(8):2038-44
references: 11956263
references: J Clin Oncol. 2003 Feb 15;21(4):631-7
references: 12586799
references: Ann Oncol. 2013 Aug;24(8):2136-46
references: 23613477
references: Radiother Oncol. 2009 Jul;92(1):105-10
references: 19264368
references: Oncol Lett. 2013 Aug;6(2):427-431
references: 24137340
references: PLoS One. 2013;8(2):e56208
references: 23441169
references: N Engl J Med. 2007 Oct 25;357(17):1705-15
references: 17960013
references: Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1481-6
references: 19386431
references: Auris Nasus Larynx. 2011 Feb;38(1):108-13
references: 20591592
references: Ann Oncol. 2012 Feb;23(2):427-35
references: 21525406
references: J Clin Oncol. 2009 Jan 10;27(2):242-9
references: 19064973
references: Oral Oncol. 2012 Oct;48(10):1038-44
references: 22591726
references: J Clin Oncol. 2005 Feb 20;23(6):1118-24
references: 15657403
references: Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):161-8
references: 16542792
references: Radiother Oncol. 2014 Mar;110(3):398-403
references: 24231245
references: Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):47-56
references: 16377415
references: Radiother Oncol. 2007 Oct;85(1):29-35
references: 17889386